VANCOUVER, British Columbia, April 29, 2020 (GLOBE NEWSWIRE) -- Canadian Blood Services is proud to be part of CONCOR, a national clinical trial to test the safety and effectiveness of COVID-19 convalescent plasma as a possible treatment to help patients infected with the virus. Today, the national blood authority and operator collected its first COVID-19 convalescent plasma donation in Vancouver.
Im delighted to be able to help out a really good cause. I have been an active blood donor for 15 years. Im pleased my unfortunate situation can help somebody else. I think Im doing a little bit of good out of all this. says Jerry Glubisz, Canadian Blood Services first COVID-19 convalescent plasma donor.
Canadian Blood Services is establishing a national convalescent plasma collection program. The blood operator is now recruiting potential convalescent plasma donors across the country through its new online registry.
Convalescent plasma may help patients recover from COVID-19, but this has not yet been proven. Well-designed clinical trials, like CONCOR, will help provide the necessary information about whether this is a safe and effective treatment option for patients, says Dr. Dana Devine, chief scientist with Canadian Blood Services. Were making an important contribution to research on a global scale that could help patients in Canada and around the world.
Over the next few weeks more convalescent plasma donors, like Jerry Glubisz, may donate at one of 11 Canadian Blood Services donor centres that have the capability to collect blood components, like plasma, through a process called apheresis. These donor centres are located in Vancouver, Calgary, Edmonton, Saskatoon, Regina, Winnipeg, London, Hamilton, Toronto, Ottawa and Halifax.
Initially, all convalescent plasma donations will be supplied to Canadian physicians caring for patients with COVID-19 in the context of the CONCOR trial and under the authorization of Health Canada.
Including both of Canadas public blood operators (Canadian Blood Services and Hma-Qubec), there are 10 research teams and more than 50 hospitals across the country currently participating in CONCOR. Patient involvement in the clinical trial will be determined by their treating physician at a participating hospital in consultation with the patient and/or the patients family. Patients with COVID-19 who are looking for more information on convalescent plasma as a treatment option are encouraged to visit CONCOR1.ca.
While Canadian Blood Services has officially started collecting convalescent plasma, these donations must still undergo all necessary testing and processing before being issued for use by physicians, as per blood safety and quality standards. Transfusions of convalescent plasma are expected to begin within a few weeks when the trial begins.
A convalescent plasma donation is the same as a plasma donation; however, a specific donor is needed for this clinical trial. In addition to meeting Canadas current plasma donor eligibility criteria, convalescent plasma donors must be younger than 67 years of age, previously confirmed positive for COVID-19 by a laboratory test, and fully recovered from the virus and symptom free for at least 28 days to participate. Donors must also live within driving distance of a donor centre located in one of the aforementioned cities. Anyone who meets these requirements is encouraged to join Canadian Blood Services online registry. Additional testing will be done at the time of collection to ensure there are adequate antibodies against the COVID-19 virus in the donors plasma to be part of the trial.
Registered convalescent plasma donors who may be eligible are being contacted now and all convalescent plasma donation appointments are being booked as donors are qualified to participate by Canadian Blood Services Centre for Innovation which oversees research and development for the organization.
Canadian Blood Services is not accepting walk-in donors for any of its collection programs during the pandemic.
Media assets
As per current physical distancing measures, media are not permitted to visit Canadian Blood Services donor centres. To ensure media have access to assets necessary to provide coverage, raw footage and an uncut interview with Canadian Blood Services first convalescent plasma donor will be made available.
Web-based interviews with Mr. Glubisz and with convalescent plasma donors in other areas of Canada may also be arranged through Canadian Blood Services.
Please contact media@blood.ca for more information.
About Canadian Blood Services
Canadian Blood Services is a not-for-profit charitable organization. Regulated by Health Canada as a biologics manufacturer and primarily funded by the provincial and territorial ministries of health, Canadian Blood Services operates with a national scope, infrastructure and governance that make it unique within Canadian healthcare. In the domain of blood, plasma and stem cells, we provide services for patients on behalf of all provincial and territorial governments except Quebec. The national transplant registry for interprovincial organ sharing and related programs reaches into all provinces and territories, as a biological lifeline for Canadians.
About Canadian Blood Services Research Activities
Canadian Blood Services, through its Centre for Innovation, conducts and supports research projects in key priority areas that span the translational continuum from bench to bed side. The focus is on transfusion science and medicine but also related fields such as cellular therapies (in particular hematopoietic stem cell transplantations) and organ and tissue transplantation. Our research findings are published in peer-reviewed journals or directly shared with stakeholders.
Instrumental to our research efforts are discovery and applied research laboratories led by university-affiliated Canadian Blood Services staff scientists, as well as our medical experts and adjunct scientists. Complementing these core research teams, the Centre for Innovation facilitates a national and international research network of blood system experts through competitive research funding opportunities, collaborations and contract research.
/CanadasLifeline@CanadasLifeline1 888 2DONATE
FOR MORE INFORMATIONTEL. 1-877-709-7773EMAILmedia@blood.ca
Continue reading here:
- Cell Therapy Market Size is Projected to Reach USD 33.93 - GlobeNewswire - January 28th, 2025
- Meet the California Institute Pushing Stem Cell & Gene Therapy Research: Part 3 - The Medicine Maker - January 28th, 2025
- Immusoft to Present Positive Data from the First Engineered B Cell in a Human Clinical Trial at the 21st Annual WorldSymposium 2025 - The Eastern... - January 28th, 2025
- Beyond the Lab: Stem cell research - Drug Target Review - January 25th, 2025
- Asia Pacific Stem Cell Therapy Market to Reach US$ 4,075.75 Million by 2033 with a Robust CAGR of 10.29% - openPR - January 25th, 2025
- Exciting data: S.Biomedics preps US IND of PD cell therapy - BioWorld Online - January 25th, 2025
- $24.85 Billion Cell Therapy Market Forecast by 2032 (CAGR 20.4%) - openPR - January 25th, 2025
- Stem Cell Therapy Market Expected to Expand at a Steady 2025-2032 - openPR - January 25th, 2025
- Regenerative Medicine Market to receive overwhelming hike US$ 164.9 billion in Revenues by 2032, Growing at a CAGR of 23.30% From 2024 to 2032 -... - January 25th, 2025
- Alternative medicine fans see RFK Jr. as a hero. The fields skeptics worry. - The Washington Post - January 23rd, 2025
- U.S. PRP and Stem Cell Alopecia Treatment Market Analysis 2025-2030 by Treatment, Indication, and End-use - Androgenic Alopecia Dominated the Market... - January 23rd, 2025
- The Future of Regenerative Medicine Lies in the Hands of Chiropractors - Dynamic Chiropractic - January 23rd, 2025
- Stem Cell Therapy Industry Dynamics and Contributions by RTI - openPR - January 21st, 2025
- Stem Cells Market to Reach USD 44.27 Billion by 2033, Driven by Expanding Applications and Innovations - openPR - January 21st, 2025
- Organoids at the Forefront Innovations in Stem Cell Research and Precision Medicine - openPR - January 21st, 2025
- The promising future of regenerative medicine - Yahoo Finance - January 17th, 2025
- An earful of gill: USC Stem Cell study points to the evolutionary origin of the mammalian outer ear - EurekAlert - January 11th, 2025
- Aspen Partners with Mytos to Automate Stem Cell Production for Parkinsons Therapy - Genetic Engineering & Biotechnology News - January 9th, 2025
- School of Medicine professor receives grant to study improved cancer treatments - Mercer University - January 9th, 2025
- Meet CIRM: the California Institute Pushing Stem Cell and Gene Therapy Research: Part 1 - The Medicine Maker - January 7th, 2025
- Regenerative Medicine Market to Experience Significant Growth, Projected to Reach $183.08 Billion by 2031. - openPR - January 7th, 2025
- Stem-cell therapies that work: 10 Breakthrough Technologies 2025 - MIT Technology Review - January 5th, 2025
- 1st stem cell therapy, new HIV drug approved - ecns - January 5th, 2025
- Science fiction turned reality? Stem cell therapy set to repair child's heart - Ynetnews - January 3rd, 2025
- Stem Health Plus Revolutionizes Skin Regeneration with Advanced Stem Cell Skin Graft Technology - The Manila Times - January 1st, 2025
- Allogeneic Stem Cell Transplantation Market Size to Expand Lucratively by 2031 - openPR - January 1st, 2025
- Apoptotic clearance by stem cells: molecular mechanisms for recognition and phagocytosis of dead cells - Nature.com - December 30th, 2024
- Why Medical Tourists are Choosing Mexico: The Affordable Alternative for Advanced Stem Cell Treatments - openPR - December 30th, 2024
- Induced Pluripotent Stem Cells (iPSC) Production Market: Trends, Growth, and the Role of AI - openPR - December 30th, 2024
- Stem cells 'instructed' to form specific tissues and organs - New Atlas - December 28th, 2024
- Stem Cell Transplantation Still the Main Treatment Option for Beta-Thalassemia - Medpage Today - December 28th, 2024
- Black Group Investment Partners with Zenzic Oasis to Advance Stem Cell Therapy for Personalised Medicine - Galveston County Daily News - December 28th, 2024
- Black Group Investment Partners with Zenzic Oasis to Advance Stem Cell Therapy for Personalised Medicine - Voice Of Alexandria - December 28th, 2024
- U.S. Stem Cell Therapy Market Revenue to Attain USD 17.70 Bn by 2033 - Precedence Research - December 27th, 2024
- Here are some biggest medical breakthroughs of 2024 - Medical Buyer - December 27th, 2024
- Researchers from Korea University explore how ascorbic acid and FGF4 revolutionize regenerative medicine - EurekAlert - December 27th, 2024
- Regenerative Medicine Market to Skyrocket to USD 73,084.2 Million by 2033 at a 18.5% of CAGR - openPR - December 27th, 2024
- Stem cell therapy to correct heart failure in children could 'transform lives' - Fox News - December 25th, 2024
- Advancing type 1 diabetes therapy: autologous islet transplant breakthrough - Nature.com - December 25th, 2024
- Stem Cell Therapy Market to Triple in Value, Reaching USD 52.1 Billion by 2034 at a 12.1% of CAGR - openPR - December 25th, 2024
- Stem-cell therapies: A breakthrough in treating parkinson's, cancer, diabetes, and more - The Business Standard - December 25th, 2024
- Replay 2024 : 6 Biggest Medical Breakthroughs Of 2024 - NewsX - December 25th, 2024
- Tumbling stem cells? Watch how movement plays a part in their fate - Scope - December 20th, 2024
- SCD patients free of VOEs after treatment with gene-editing therapy - Sickle Cell Disease News - December 20th, 2024
- Japan's Sumitomo to establish regenerative medicine and cell therapy joint venture - BSA bureau - December 20th, 2024
- Brain cells remain healthy after a month on the International Space Station, but mature faster than brain cells on Earth - EurekAlert - December 19th, 2024
- Reindeers Pave the Way for Regenerative Medicine - The Scientist - December 19th, 2024
- Johnson & Johnson submits application to the European Medicines Agency seeking approval of a new indication for IMBRUVICA (ibrutinib) in adult... - December 19th, 2024
- What Role Does Regenerative Medicine Play In The Management Of Type 1 And Type 2 Diabetes? - TheHealthSite - December 19th, 2024
- World's 1st Stem Cell Book on Animals, Reveals How to Extend the Lives of Pets - PR Newswire - December 17th, 2024
- Accelerated Biosciences and Stemmatters Collaborate to Offer iPSC Derived from Human Trophoblast Stem Cells - Business Wire - December 17th, 2024
- Stem Cells: Hope on the Horizon for Preterm Babies - Monash University - December 17th, 2024
- Stem Cell Transplant Offers No Difference in OS or PFS in Mantle Cell Lymphoma Compared with Maintenance Therapy Alone - OncoZine - December 17th, 2024
- Inside One Mans Journey with Multiple Myeloma - Men's Health - December 15th, 2024
- Stem Cells Market Size to Reach USD 48.83 Billion By 2034 - Exclusive Report by Precedence Research - BioSpace - December 13th, 2024
- Treating Heart Defects with Tissue-engineered Vascular Conduits - Yale School of Medicine - December 13th, 2024
- Tom Curry: England flanker has stem-cell therapy in bid to make 2027 World Cup - BBC.com - December 13th, 2024
- Stem Cell Manufacturing Market Dynamics Key Drivers Challenges and Technological Innovations - Set to reach USD 26.6 billion by 2033 - PharmiWeb.com - December 13th, 2024
- Stem Cell Therapy Market Is Expected To Reach Revenue Of USD 54.7 Bn By 2033, At 12.6% CAGR: Dimension Market Research - The Manila Times - December 13th, 2024
- Stem cell transplantation could save the coral reefs - Ynetnews - December 13th, 2024
- Vitrification Market | Driving Innovations in Cryopreservation for Fertility Treatments and Regenerative - EIN News - December 13th, 2024
- Workshop on Regenerative Medicine concludes at SKUAST-K - Greater Kashmir - December 13th, 2024
- High-dose chemotherapy followed by autologous stem cell transplant ineffective for patients with mantle cell lymphoma - News-Medical.Net - December 11th, 2024
- Stem Cell Therapy Market Is Expected To Reach Revenue Of - GlobeNewswire - December 11th, 2024
- Stem Cell Therapy Market to Worth Over US$ 2,612.92 Million By 2033 | Astute Analytica - GlobeNewswire - December 11th, 2024
- Changes in Blood Cell Production Over the Lifetime | Newswise - Newswise - December 7th, 2024
- Study reveals how stem cells respond to environmental signals, with implications for IBD and colorectal cancer - Medical Xpress - December 5th, 2024
- Stem cell therapy TED-A9 showing safety and early efficacy in trial - Parkinson's News Today - December 5th, 2024
- BMP-2 loaded scaffold for stem and immune cell recruitment in therapeutic applications - News-Medical.Net - December 5th, 2024
- Stem Cell Treatment May Help To Cure Vision Loss - Anti Aging News - December 5th, 2024
- BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024... - December 3rd, 2024
- Stem Cell Therapy Strategic Business Report 2024 - - GlobeNewswire - December 3rd, 2024
- Enhancing the efficacy of cell transplantation therapy for stroke or traumatic brain injury - Medical Xpress - December 1st, 2024
- Apheresis in Cellular Therapies: Unlocking Quality for CAR T and Stem Cell Treatments, Upcoming Webinar Hosted by Xtalks - PR Web - November 29th, 2024
- Stem Cell Therapy Market is expected to Double Its Size by Upcoming Decade - openPR - November 29th, 2024
- AmeraCell Revolutionizes Regenerative Medicine with Accessible and Affordable Stem Cell Clinics - openPR - November 29th, 2024
- Making fat cells skinny: Findings could lead to new, more effective therapies for managing diabetes - Medical Xpress - November 25th, 2024
- Designer Cells Could Be the Key to Autoimmune Disease Treatment - VICE - November 25th, 2024
- Why do athletes store their body cells? - The Times of India - November 22nd, 2024
- What Stem Cell Treatments Canand CantDo - Men's Health - November 22nd, 2024
Recent Comments